Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT02930837
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT02930837
-
- Other papers using this trial's data
- Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02930837. Allocation not applicable; no masking; primary purpose treatment. Start 2016-11-15 (actual); primary completion 2017-12-11 (actual). Results posted on 2019-08-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
- Condition
- Stroke
- Intervention (Drug)
- alteplase
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct02930837- Content hash
2c6cd7d16d885200783b90cb9db6d96390dc165eea3cac79bf3d86565bcaad11